Loading
A blood test for inherited BRCA mutations unlocks a year of olaparib after surgery, which improves survival.
This diagnostic-therapeutic pairing links Germline (hereditary) testing for inherited BRCA1 / BRCA2 (HRD) mutations to a year of adjuvant Olaparib, one of the PARP inhibitors, after surgery. The rationale is synthetic lethality confined to BRCA-deficient cells, so the drug is only worth giving once the inherited mutation is confirmed. The phase 3 OlympiA trial showed that adjuvant olaparib improved invasive disease-free survival and overall survival in this population. Because the treatment depends on the test, every patient with Triple-negative breast cancer (TNBC) or high-risk HR-positive / HER2-negative breast cancer needs germline testing at diagnosis, which is why the pairing is linked from the TNBC and Germline testing entries.
Shares OlympiA, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
Shares PARP inhibitors, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Germline (hereditary) testing.
Shares OlympiA, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
Shares OlympiA, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
Shares OlympiA, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Germline (hereditary) testing.
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Germline (hereditary) testing, Triple-negative breast cancer (TNBC).
Shares OlympiA, Olaparib, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Germline (hereditary) testing, Triple-negative breast cancer (TNBC).